Press Release Source: Decision Resources, Inc.
Tuesday September 5, 8:00 am ET
New Drug Launches Will Propel Neuroprotectant Sales to Nearly $3 Billion in 2020, According to a New Report from Decision Resources
WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that neuroprotectants, including drugs from AstraZeneca/Renovis and Sanofi-Aventis, have the potential to revolutionize the treatment of several neurologic indications. Neuroprotectants will be used to treat acute neurologic indications such as acute ischemic stroke (AIS) and traumatic brain injury as well as neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
According to the new Pharmacor report entitled Neuroprotection: Analysis of Drug Development and Emerging Therapies, neuroprotectants will launch in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan during the 2005 - 2020 study period, beginning with the launch in 2008 of AstraZeneca/Renovis's NXY-059 for the treatment of AIS.
The report finds that the high prevalence of AIS combined with the extensive unmet need for a safe treatment for the disease, and off-label use in the United States, will drive NXY-059 to blockbuster status with sales in the United States and Europe reaching over $1.5 billion in 2020. Along with NXY-059, Sanofi-Aventis's Xaprila (xaliprodene) and SR-57667 will be major players in this market, driving sales of neuroprotectants to nearly $3 billion in 2020. Sales of xaliprodene and SR-57667 will total over $1.2 billion by 2020, driven by the high prevalence of Alzheimer's disease and the requirement for chronic administration of these drugs. However, significant challenges exist in this market, compared to AIS.
"Prior to NXY-059's successful completion of the first Stroke Acute Ischemic NXY Treatment (SAINT-1) trial, approval for a neuroprotectant was elusive in the United States and Europe," said Andrea Witt, Ph.D., analyst at Decision Resources, Inc. "If the second SAINT trial provides similar results, the approval of NXY-059 will set a drug development and regulatory precedent by renewing the interest of drug makers in this field and will pave the way for the development of emerging neuroprotectants over the next decade."
Neuroprotectants are agents that have the potential to prevent neuronal death after injury that could be used in a wide range of neurologic indications, all characterized by acute unmet need.